Infanrix Polio (Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads)

Pertussis Filamentous Haemagglutinin is an acellular pertussis antigen adsorbed onto aluminium hydroxide. When injected, it is recognized by the immune system, prompting antigen‑presenting cells to activate B‑cells and T‑cells. This leads to the production of specific antibodies and cellular immunity that neutralise the pertussis bacterium.

The dosage and schedule of Infanrix Polio are determined by the prescribing healthcare professional based on national immunisation guidelines. Typically, the vaccine is given as a series of intramuscular injections at specific ages, but the exact timing and number of doses are set by the child's physician.

Infanrix Polio is generally not recommended for use in pregnant women unless the potential benefit outweighs any risk, as safety data are limited. Breastfeeding is not a contraindication, but mothers should discuss vaccination with their healthcare provider to assess individual circumstances.

To order Infanrix Polio, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, cold‑chain shipping details and any required import documentation.

Infanrix Polio is comparable to other DTaP‑IPV vaccines such as Pentacel or Pediarix, offering protection against the same four pathogens. Differences may include specific antigen formulations, adjuvant types, and approved age schedules. Clinicians choose a product based on national guidelines, availability, and individual patient considerations.

Infanrix Polio must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to administration, the vial should be inspected for particulate matter and used within the time frame indicated by the manufacturer.

Infanrix Polio is given as an intramuscular injection, usually into the anterolateral thigh of infants or the deltoid muscle of older children. The injection is performed by a qualified healthcare professional following the recommended immunisation schedule, and the site should be observed for any immediate reactions.

The most serious adverse events reported with Infanrix Polio include anaphylactic reactions, seizures, high‑grade fever, and, rarely, Guillain‑Barré syndrome. Any signs of severe allergic response—such as difficulty breathing, swelling of the face or throat, or rapid heartbeat—require immediate medical attention.

Infanrix Polio should not be given to individuals with a known severe allergy to any component of the vaccine, including aluminium hydroxide or the pertussis antigens. It is also contraindicated in persons who have experienced a previous anaphylactic reaction to a DTaP‑IPV vaccine. Consultation with a healthcare provider is essential for anyone with a history of severe neurological disorders.